Form 6-K Summary
Issuer and period: The filing identifies the issuer as I-MAB, not Novabridge Biosciences. It is a Form 6-K for the month of May 2023, filed May 1, 2023, under Commission File No. 001-39173.
Business Context and Reporting Period
The filing is a supplemental submission under Item 16I(a) of Form 20-F concerning the Holding Foreign Companies Accountable Act (HFCAA). It does not provide operating or financial results for the period.
HFCAA Status and Ownership Information
- I-MAB was conclusively identified by the SEC as a Commission-Identified Issuer on May 26, 2022, because its 2021 Form 20-F included an audit report issued by PricewaterhouseCoopers Zhong Tian LLP, a mainland China-based accounting firm.
- The filing notes that the PCAOB vacated its prior determination regarding its inability to inspect or investigate completely registered accounting firms headquartered in mainland China in December 2022.
- The company states that, based on its knowledge, it is not owned or controlled by a governmental entity of China and is not aware of any Chinese governmental entity otherwise controlling it.
Ownership Disclosures as of March 31, 2023
| Holder or group | Reported ownership |
|---|---|
| C-Bridge entities | Approximately 15.3%, based on holdings reported as of December 31, 2022 |
| Hillhouse entities | Approximately 8.6%, based on holdings reported as of September 23, 2021 |
| GIC Private Limited | Approximately 6.3%, based on holdings reported as of December 31, 2022; GIC is wholly owned by the Government of Singapore |
| Infini Master Fund | Approximately 6.0%, based on holdings reported as of May 31, 2022 |
| Dr. Jingwu Zhang Zang | Approximately 5.5% |
| Directors and senior management | Approximately 21.4% collectively |
Several ownership percentages are based on historical beneficial ownership reports and assume that the relevant holdings had not changed as of March 31, 2023.
Financial Metrics and Material Changes
The filing does not provide revenue, profit, cash flow, margins, debt, liquidity, guidance, or other operating metrics. It also does not report a comparable-period financial change or an unusual financial item.
Risks, Contingencies, and Management Commentary
- The HFCAA designation creates regulatory and potential trading or listing risks if the company is deemed to have insufficiently addressed PCAOB inspection-related requirements in future periods.
- The company’s conclusion that it is not controlled by a Chinese governmental entity is based on available ownership records, public filings, and the company’s knowledge.
- The filing references the company’s 2022 Form 20-F, filed May 1, 2023, for additional ownership details.
Investor Verification Items
- Verify that the filing and issuer are I-MAB rather than Novabridge Biosciences.
- Confirm current beneficial ownership, particularly where the filing relies on historical reports and assumptions that holdings did not change.
- Review the company’s 2022 Form 20-F for detailed ownership, control, and HFCAA disclosures.
- Monitor subsequent SEC and PCAOB developments affecting Commission-Identified Issuer status and potential trading or listing consequences.